Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.

about

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation.Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis

P2860

Q52652986-D295342B-2D5B-44A1-83A8-3D5038392CB4 Q57144495-DE1623DC-8A93-46F9-8765-69E659BABD0A

P2860

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.

Item

http://www.wikidata.org/entity/Q37707704

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Construction of a novel cell-b ...... fficacy against EGFR mutation.

@en

Construction of a novel cell-b ...... fficacy against EGFR mutation.

@nl

type

Item

label

Construction of a novel cell-b ...... fficacy against EGFR mutation.

@en

Construction of a novel cell-b ...... fficacy against EGFR mutation.

@nl

prefLabel

Construction of a novel cell-b ...... fficacy against EGFR mutation.

@en

Construction of a novel cell-b ...... fficacy against EGFR mutation.

@nl

P1476

Construction of a novel cell-b ...... fficacy against EGFR mutation.

@en

P2093

Ai Wakamatsu

http://www.w3.org/2001/XMLSchema#string

Arisa Higa

http://www.w3.org/2001/XMLSchema#string

Gen Hiyama

http://www.w3.org/2001/XMLSchema#string

Hirotaka Hoshi

http://www.w3.org/2001/XMLSchema#string

Jiro Fujimoto

http://www.w3.org/2001/XMLSchema#string

Kentaro Semba

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Inageda

http://www.w3.org/2001/XMLSchema#string

Kosuke Ishikawa

http://www.w3.org/2001/XMLSchema#string

Motoki Takagi

http://www.w3.org/2001/XMLSchema#string

Naoki Goshima

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Cancer statistics, 2013

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

66-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OR.2016.5227

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27840973

http://www.w3.org/2001/XMLSchema#string

P932

5355725

http://www.w3.org/2001/XMLSchema#string

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.

about

P2860

P2860

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932